Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discharge After Transcatheter Aortic Valve Implantation: Observational Study of Self-Reported Experiences and Health Status in the Very Early Recovery Period.

Structural heart : the journal of the Heart Team·2026

Same authorSame journal

Effect of Nominal-Volume ("Double Tap") Postdilatation on Significant THV Mid-Stent Frame Underexpansion After Balloon-Expandable TAVR.

JACC. Cardiovascular interventions·2026

Same author

Sex differences in echocardiographic left ventricular remodeling and clinical outcomes following transcatheter aortic valve implantation.

Journal of echocardiography·2026

Same author

Weeks-Ahead Epidemiological Predictions of Varicella Cases From Univariate Time Series Data Applying Artificial Intelligence.

Infectious diseases & immunity·2026

Same author

Modification of Calcified Native and Surgical Bioprosthetic Aortic Valves: Lessons From the Bench.

JACC. Cardiovascular interventions·2026

Same author

Leaflet Modification for Redo-TAVR: Impact of Valve Type, Expansion, and Failure Mode-A Bench Study.

JACC. Cardiovascular interventions·2026

Same journal

Double Transseptal Guide Sheath Technique to Prevent Low Dock Positioning During Transcatheter Mitral Valve Replacement.

JACC. Cardiovascular interventions·2026

Same journal

Real-World Outcomes of Dedicated Leaflet Modification for Bioprosthetic Valve-In-Valve TAVR: A 150-Patient Commercial Experience.

JACC. Cardiovascular interventions·2026

Same journal

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026

Same journal

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026

Same journal

REPLY: The Angiographic Veto: Putting the Operator Back in DAPT De-Escalation.

JACC. Cardiovascular interventions·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

An embolic deflection device for aortic valve interventions.

Fabian Nietlispach¹, Namal Wijesinghe, Ronen Gurvitch

¹Department of Cardiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.

JACC. Cardiovascular Interventions

|November 20, 2010

Summary

This summary is machine-generated.

A new cerebral embolic protection device shows promise for reducing stroke risk during transcatheter aortic valve interventions. Initial human use demonstrated feasibility and safety, with no new neurological symptoms observed in patients.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jun 6, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Cardiovascular Surgery
Neurology
Medical Device Technology

Background:

Cerebral emboli are a primary cause of stroke during percutaneous aortic valve interventions.
Transcatheter aortic valve interventions (TAVI) carry a risk of embolic complications affecting the brain.
Protecting cerebral circulation during these procedures is critical.

Purpose of the Study:

To evaluate the initial human experience with a novel cerebral embolic protection device.
To assess the feasibility, safety, and potential efficacy of this device during TAVI.
To investigate the impact on procedural time and cerebral perfusion.

Main Methods:

A novel embolic protection device was deployed via right radial artery access into the aortic arch.
The device uses a porous membrane to shield the brachiocephalic trunk and left carotid artery.
Used in 4 patients undergoing aortic balloon valvuloplasty or TAVI; cerebral MRI performed post-procedure.

Main Results:

Device placement was successful in all patients without difficulty.
No evidence of cerebral perfusion obstruction was detected via pressure monitoring.
No new neurological symptoms or stroke findings occurred; one asymptomatic infarct noted after balloon valvuloplasty alone.

Conclusions:

Cerebral embolic protection during TAVI appears feasible with this novel device.
The device may potentially reduce the risk of cerebral embolism and subsequent stroke.
Further investigation is warranted to confirm its clinical benefit.